We performed a comprehensive systematic review and meta‐analysis to evaluate the value of PD‐L1 expression for predicting the clinical response to PD‐1/PD‐L1 inhibitors in clinical trials including patients with advanced HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.